Form HLTH5482 Pharmacare Special Authority Request - Alemtuzumab (Lemtrada) for Multiple Sclerosis - British Columbia, Canada

The Form HLTH5482 Pharmacare Special Authority Request - Alemtuzumab (Lemtrada) for Multiple Sclerosis in British Columbia, Canada is used to request special authority for reimbursement of Alemtuzumab (Lemtrada) medication for the treatment of Multiple Sclerosis. It is specific to the Pharmacare program in British Columbia.

The Form HLTH5482 Pharmacare Special Authority Request - Alemtuzumab (Lemtrada) for Multiple Sclerosis in British Columbia, Canada is typically filed by the patient's healthcare provider or doctor.

FAQ

Q: What is Alemtuzumab (Lemtrada)?
A: Alemtuzumab (Lemtrada) is a medication used to treat multiple sclerosis.

Q: What is Multiple Sclerosis?
A: Multiple Sclerosis is a chronic autoimmune disease that affects the central nervous system.

Q: What is Pharmacare Special Authority Request?
A: Pharmacare Special Authority Request is a process in British Columbia, Canada, where patients can request coverage for medications not typically covered by the provincial drug plan.

Q: How do I request special authority for Alemtuzumab (Lemtrada) in British Columbia?
A: You can request special authority for Alemtuzumab (Lemtrada) by filling out the HLTH5482 form.

Q: Is Alemtuzumab (Lemtrada) covered by the provincial drug plan in British Columbia?
A: Alemtuzumab (Lemtrada) is not typically covered by the provincial drug plan in British Columbia, hence the need for a special authority request.

Q: What are the requirements for a successful special authority request for Alemtuzumab (Lemtrada)?
A: The specific requirements for a successful special authority request can be found in the HLTH5482 form and should be followed accordingly.